Memo - Magazine of European Medical Oncology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A CONGRESS DIGEST ON NEUROENDOCRINE TUMORS. Report from the North American Neuroendocrine Tumor Society (NANETS) Annual Medical Symposium, 27th – 29th October 2022, Washington
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 26, 2023 Category: Cancer & Oncology Source Type: research
A CONGRESS DIGEST ON RADIOLABELED THERANOSTICS FOR SOLID TUMORS. Report from the 35th Annual Congress of the European Association of Nuclear Medicine (EANM), October 15th – 19th, 2022, Barcelona
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 26, 2023 Category: Cancer & Oncology Source Type: research
A GLOBAL CONGRESS DIGEST ON ON APPROACHES IN ADVANCED SOLID TUMORS. Report from the ESMO Immuno-Oncology Congress, 7th – 9th December 2022
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 20, 2023 Category: Cancer & Oncology Source Type: research
Excellent response of a disseminated SMARCA4-deficient thoracic sarcomatoid tumor to immunochemotherapy—a case report
SummaryA 68-year-old man was diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Immunochemotherapy with carboplatin, paclitaxel, and pembrolizumab followed by maintenance therapy with pembrolizumab resulted in clinically meaningful remission. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 20, 2023 Category: Cancer & Oncology Source Type: research
Selection of phase II/III breast cancer study highlights at the 2022 ESMO annual meeting
This article aims at presenting highlights of phase II and III clinical trials reported at this meeting. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 20, 2023 Category: Cancer & Oncology Source Type: research
A GLOBAL CONGRESS DIGEST ON ON APPROACHES IN ADVANCED SOLID TUMORS. Report from the ESMO Immuno-Oncology Congress, 7th – 9th December 2022
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 20, 2023 Category: Cancer & Oncology Source Type: research
Excellent response of a disseminated SMARCA4-deficient thoracic sarcomatoid tumor to immunochemotherapy—a case report
SummaryA 68-year-old man was diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Immunochemotherapy with carboplatin, paclitaxel, and pembrolizumab followed by maintenance therapy with pembrolizumab resulted in clinically meaningful remission. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 20, 2023 Category: Cancer & Oncology Source Type: research
Selection of phase II/III breast cancer study highlights at the 2022 ESMO annual meeting
This article aims at presenting highlights of phase II and III clinical trials reported at this meeting. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 20, 2023 Category: Cancer & Oncology Source Type: research
A GLOBAL CONGRESS DIGEST ON TARGETED THERAPIES IN B-CELL MALIGNANCIES AND AML. Report from the American Society of Hematology (ASH) Annual Meeting, December 10 –13, 2022
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 18, 2023 Category: Cancer & Oncology Source Type: research
Assessment of nutritional status using objective and subjective methods in Greek patients with cancer
ConclusionThe present study highlighted a high risk of malnutrition in patients with cancer. Poor nutritional status was positively associated with weight loss, Hgb, and MUAC and negatively associated with BMI, HGS, and TSF. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 22, 2023 Category: Cancer & Oncology Source Type: research
ESMO 2022: spotlight on new emerging treatment options in central nervous system tumors
SummaryNearly 40 abstracts regarding tumors of the central nervous system were presented at the European Society for Medical Oncology (ESMO) Congress in September 2022. While no practice-changing data were shown, interesting early phase clinical trial results on immune-modulating agents, targeted treatments and o ther therapeutic modalities were revealed (Table 1). In this short review, we aim to summarize our personal highlights of the presented data and outline future perspectives in the field. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 20, 2023 Category: Cancer & Oncology Source Type: research
Position paper on CDK4/6 inhibitors in early breast cancer
SummaryInhibitors of the cyclin-dependent kinases 4/6 (CDK4/6i) have been practice-changing and are now considered the standard of care in combination with endocrine therapy for the first- or second-line treatment in advanced hormone-receptor-positive, human epidermal growth factor receptor 2 ‑negative breast cancer. Recently, CDK4/6i have also emerged as an appealing targeted cancer therapy in early breast cancer, however results of large clinical trials are controversial. This position paper summarizes the evidence, and provides guidance for clinical practice. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 14, 2023 Category: Cancer & Oncology Source Type: research
